- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Salix Pharmaceuticals Ltd
+ Add to WatchlistSLXP:US
66.4200 USD 0.4100 0.61%
Share
As of 20:10:00 ET on 06/19/2013.
More on SLXP
News for Salix Pharmaceuticals Ltd (SLXP)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Sucampo Wins Approval for Expanded Use of Amitiza in U.S.
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Largest Nasdaq Short Interest Changes as of Dec. 31
- Drug Approvals Reach 15-Year High on Smoother FDA Reviews
- Salix Wins FDA Approval of Dragon’s Blood Drug for Diarrhea
- Salix Dragon’s Blood Drug for Diarrhea Delayed by FDA
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Progenics Plummets on Rejection of New Use of Relistor Drug
- Forest Labs Seen Needing Deal Amid Patent Loss: Real M&A
- Kingdon Capital Management Holdings in 4th Quarter: 13F Alert
- U.S. Stock Options With Biggest Changes in Implied Volatility
- TCW Group Incorporated Holdings in 4th Quarter: 13F Alert
- CVS, Juniper, Progenics, PulteGroup, Sprint: U.S. Equity Movers
- Progenics Rises as Constipation Drug Shows Benefits in Trial
- Career Education, Green Mountain, VeriFone: U.S. Equity Movers
- Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock Published 6 hours ago
- Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Published Jun 11, 2013
- New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix Published Jun 06, 2013
- The Zacks Analyst Blog Highlights: Eli Lilly, Teva, Salix Pharmaceuticals, Santarus and Turkcell Iletisim Hizmetleri Published Jun 05, 2013
- Progenics Pharmaceuticals to Present at Jefferies Global Healthcare Conference Published May 31, 2013
- Salix Pharmaceuticals to Present at Two Investment Conferences in June Published May 30, 2013
- Salix Pharmaceuticals Acquires Worldwide Rights to Olon’s Intellectual Property Relating to Amorphous Rifaximin Published May 30, 2013
- Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Published May 22, 2013
- Pfizer Share Swap for Animal Health Stake Hits Top Limit Updated 3 hours ago
- U.S. Company Credit Swaps Rise Most in Year After Fed Statement Updated 4 hours ago
- Cancer-Causing Sex Virus Cut in Teen Girls by Vaccines
- Nektar Therapeutics Gains on Trial of New Painkiller
- Valeant Plans $7.3 Billion in Loans, Bonds for Bausch Purchase
- Valeant Seeks $4.05 Billion in Loans for Bausch & Lomb Purchase
- To Taper or Not?: In The Loop (06/18)
- Lundbeck Fined $125.6 Million by EU Drug Delay Probe
- Marathon Patent, Novo Nordisk: Intellectual Property
- Swiss Stocks Decline Before Fed Statement on Stimulus
- Almirall CEO on International Expansion, Porfolio
- Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel
- Medtronic’s Infuse No Better Than Bone Graft With Risk
- FDA Investigating Lilly’s Zyprexa Injection After Two Die
- Global Power Players: In The Loop (06/14)
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page